RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
A phase 2 trial of RVU120 (SEL120) in myelodysplastic syndromes / neoplasms, run by GCP-Service International West GmbH, active and no longer recruiting.
Overview
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms is a phase 2 interventional study registered as NCT06243458 by GCP-Service International West GmbH, with 41 participants enrolled, started 2024-09-10 and due to reach its primary completion in 2026-05. Interventions recorded: RVU120 (SEL120).
Similar pages
not linked directly; found by shared links- TrialFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialA Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialPBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TreatmentMEN1703
Shares Ryvu Therapeutics and the tag pipeline.
- TrialSafety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Shares Ryvu Therapeutics and the tag pipeline.
- TrialStudy of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialStudy of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.